LENZ Therapeutics
LENZ
62 hedge funds and large institutions have $72.9M invested in LENZ Therapeutics in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 16 closing their positions.
0.24% more ownership
Funds ownership: 7.06% → 7.31% (+0.24%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less call options, than puts
Call options by funds: $1.46M | Put options by funds: $1.47M
5% less funds holding
Funds holding: 65 → 62 (-3)
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
24% less capital invested
Capital invested by funds: $95.4M → $72.9M (-$22.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.53M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.17M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.15M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.43M |
| 5 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.23M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.71M |
| 3 |
AG
Artal Group
Luxembourg
|
-$2.32M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.5M |
| 5 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$847K |
LENZ Hedge Fund Activity: Q1 2023 in Review
62 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q1 2023, worth a combined $72.9M — down 24% from $95.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LENZ and 13 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 15 added.
The largest buyer was EcoR1 Capital, adding an estimated $6.53M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $5.23M sold.
- 62 institutional investors held LENZ Therapeutics (LENZ) as of Q1 2023, down from 65 in Q4 2022.
- Funds reported $72.9M of LENZ Therapeutics stock for Q1 2023, down 24% quarter-over-quarter.
- 13 funds opened new LENZ Therapeutics positions in Q1 2023 and 16 closed out, a net change of -3 holders.
- The largest LENZ Therapeutics buyer in Q1 2023 was EcoR1 Capital, an estimated $6.53M added.
- The largest LENZ Therapeutics seller in Q1 2023 was Avidity Partners Management, an estimated $5.23M sold.
Based on aggregated 13F filings for Q1 2023.